Literature DB >> 20041822

Plasticity and physiological role of stem cells derived from skeletal muscle interstitium: contribution to muscle fiber hyperplasia and therapeutic use.

Tetsuro Tamaki1, Yoshiyasu Uchiyama, Akira Akatsuka.   

Abstract

Stem cells other than satellite cells that can give rise to primary myoblasts, which are able to form additional new fibers postnatally, are present in the interstitial spaces of skeletal muscle. These cells are sorted into CD34(+)/45(-) (Sk-34) and CD34(-)/45(-) (Sk-DN) cell fractions, and they are wholly (>99%) negative for Pax7 at initial isolation. Colony-forming units of these cells typically include non-adherent type myogenic cells, while satellite cells are known to be adherent in cell culture. In addition, both Pax7(-) and Pax7(+) cells are produced, depending on asymmetric cell division. A large number of myotubes are also formed in each colony, thus suggesting that putative Pax7(+) satellite cells also present in each colony. Interestingly, interstitial myogenic cells show basal lamina formation at early stages of myogenesis in response to various types of stimulation in compensatory enlarged muscle, a property that satellite cells do not possess in the parent fiber basal lamina cylinder. Basal lamina formation and production of satellite cells are essential before muscle fiber establishment in vivo. It is therefore likely that myogenic cells in skeletal muscle can be divided into two populations: 1) basal lamina-producing myogenic cells; and 2) basal lamina-non-producing myogenic cells. The latter population may be Pax7(+) satellite cells showing adherent capacity in cell culture, while the lamina-producing myogenic population derived from interstitial multipotent stem cells, which is predominant among Sk-34 and Sk-DN cells, plays a role in primary myoblast generation and shows non-adherent behavior in culture. Therefore, the physiological role of interstitial myogenic cells is as a source for new postnatal muscle fiber formation, and multinucleated muscle fibers (cells) are potentially formed clonally.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20041822     DOI: 10.2174/138161210790883408

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Preferential and comprehensive reconstitution of severely damaged sciatic nerve using murine skeletal muscle-derived multipotent stem cells.

Authors:  Tetsuro Tamaki; Maki Hirata; Shuichi Soeda; Nobuyuki Nakajima; Kosuke Saito; Kenei Nakazato; Yoshinori Okada; Hiroyuki Hashimoto; Yoshiyasu Uchiyama; Joji Mochida
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

2.  Volitional Weight-Lifting in Rats Promotes Adaptation via Performance and Muscle Morphology prior to Gains in Muscle Mass.

Authors:  Erik P Rader; G Roger Miller; Robert D Chetlin; Oliver Wirth; Brent A Baker
Journal:  Environ Health Insights       Date:  2014-10-13

3.  Quantitative Evaluation of the Reduced Capacity of Skeletal Muscle Hypertrophy after Total Body Irradiation in Relation to Stem/Progenitor Cells.

Authors:  Tsuyoshi Fukuzawa; Toshiharu Natsume; Miyu Tamaki; Takeshi Imai; Ippei Yamato; Tetsuro Tamaki
Journal:  J Clin Med       Date:  2022-06-28       Impact factor: 4.964

4.  Human amniotic fluid stem cell injection therapy for urethral sphincter regeneration in an animal model.

Authors:  Bum Soo Kim; So Young Chun; Jong Kil Lee; Hyun Ju Lim; Jae-sung Bae; Ho-Yun Chung; Anthony Atala; Shay Soker; James J Yoo; Tae Gyun Kwon
Journal:  BMC Med       Date:  2012-08-21       Impact factor: 8.775

Review 5.  Role of Inflammation in Muscle Homeostasis and Myogenesis.

Authors:  Domiziana Costamagna; Paola Costelli; Maurilio Sampaolesi; Fabio Penna
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711

Review 6.  Bridging long gap peripheral nerve injury using skeletal muscle-derived multipotent stem cells.

Authors:  Tetsuro Tamaki
Journal:  Neural Regen Res       Date:  2014-07-15       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.